Midlab Incorporated Faces FDA Class II Recall Over Microbial Contamination in Antibacterial Hand Soap
Midlab Incorporated initiated a Class II recall for ROYALAB Germ Away Antibacterial Hand Soap due to cGMP deviations and microbial contamination. This impacts procurement and regulatory teams reliant on the Chloroxylenol 0.1% product, necessitating immediate supply chain review and robust quality assurance protocols to mitigate disruption and ensure product safety.
FDA Mandates Class II Recall for Midlab's Chloroxylenol Hand Soap Due to cGMP Deviations
Midlab Incorporated, a manufacturer based in Athens, Tennessee, has initiated a voluntary Class II recall for its ROYALAB Germ Away Antibacterial Hand Soap. This critical action, designated recall number D-0090-2025, stems from significant Current Good Manufacturing Practice (cGMP) deviations, specifically out-of-specification results for microbial contamination within the hand soap products. The affected product, identified by Lot 0711241, contains Chloroxylenol 0.1% and is packaged in one U.S. gallon (3.78 L) containers. For procurement directors and supply chain VPs, this means an immediate need to quarantine any existing inventory of this specific lot and product. The Class II classification indicates that the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Given the product's antibacterial claim, microbial contamination undermines its core purpose and poses a direct risk to public health, especially in institutional settings where such products are widely used. Business development executives should note the potential for reputational damage to both Midlab Incorporated and Royal Papers, the St. Louis, MO-based distributor listed on the product, due to this quality lapse.
Facility Profile and Product Impact: Midlab's Athens, TN Operations Under Scrutiny
Midlab Incorporated operates as a manufacturer from its facility at 140 Private Brand Way, Athens, TN 37303-1401, United States. This facility is the origin point for the ROYALAB Germ Away Antibacterial Hand Soap, a product distributed nationwide across the USA. The recall of this specific hand soap, containing Chloroxylenol 0.1%, highlights the critical importance of stringent quality control within manufacturing operations. For procurement directors, the immediate impact is a disruption in the supply of a key antibacterial product. Businesses, particularly those in healthcare, food service, or public institutions that rely on bulk hand soap supplies, must now identify and qualify alternative sources for equivalent Chloroxylenol-based or other antibacterial hand soaps. The recall's 'ongoing' status, initiated on November 6, 2024, with a center classification date of December 2, 2024, suggests that Midlab is actively engaged in addressing the issue, but the full scope of remediation and its impact on future product availability remains to be seen. Regulatory affairs heads should monitor Midlab's corrective actions closely, as any further issues could lead to escalated FDA enforcement.
Supply Chain Exposure: Mitigating Risks from Contaminated Antibacterial Products
The nationwide distribution of Midlab Incorporated's ROYALAB Germ Away Antibacterial Hand Soap means a broad spectrum of businesses across the United States are potentially exposed to this recall. Procurement teams in hospitals, schools, corporate offices, and retail chains that may have purchased Lot 0711241 of this Chloroxylenol 0.1% product face immediate operational challenges. The presence of microbial contamination in an antibacterial product not only renders it ineffective but could also introduce harmful microorganisms, directly contradicting its intended use. This scenario underscores the imperative for robust supplier qualification processes and continuous monitoring of cGMP compliance. Supply chain VPs must initiate a rapid assessment of their inventory, distribution channels, and end-user exposure to prevent further use of the recalled product. Furthermore, this event serves as a critical reminder for business development executives regarding the potential for product liability and brand erosion when quality control failures occur within the supply chain, impacting not only the manufacturer but also distributors like Royal Papers and their downstream customers.
Regulatory Context and Industry Trends: Heightened Scrutiny on Manufacturing Quality
The FDA's classification of this event as a Class II recall, despite being firm-initiated and voluntary, signals the agency's continued vigilance over manufacturing quality, particularly for products with health claims. While the ChemLifeIntel Knowledge Graph does not indicate a specific history of prior FDA actions against Midlab Incorporated, this incident aligns with a broader industry trend of heightened regulatory scrutiny on cGMP adherence. Recent parallel events, such as Essential Wellness Pharma's progesterone injection recall for sterility issues and ongoing FDA hearings impacting Amgen's market future, underscore the consistent pressure on manufacturers across the chemical and life sciences sectors to maintain impeccable quality systems. For regulatory affairs heads, this Midlab recall reinforces the need for proactive internal audits and robust quality management systems to prevent similar deviations. The FDA's consistent enforcement posture means that any firm, regardless of its historical compliance record, must uphold the highest standards to avoid significant operational disruptions and potential market access restrictions in the United States.
Remediation Timeline and Future Compliance Outlook for Midlab Incorporated
Following the recall initiation on November 6, 2024, Midlab Incorporated is now tasked with a comprehensive remediation effort to address the cGMP deviations and microbial contamination. This typically involves a thorough root cause analysis, implementation of corrective and preventive actions (CAPA), and verification of their effectiveness. For procurement directors, understanding Midlab's remediation timeline is crucial for assessing future supply stability. Inadequate or delayed corrective actions could lead to further FDA scrutiny, including potential Warning Letters or even an injunction, impacting Midlab's ability to supply the market. Regulatory affairs professionals should advise their organizations to request detailed information from Midlab regarding their CAPA plan and its execution, ensuring that the underlying issues leading to out-of-specification microbial results are fully resolved. The firm's ability to demonstrate sustained compliance will be key to restoring market confidence and ensuring the long-term availability of its products, including Chloroxylenol 0.1% based formulations, in the competitive U.S. market.